Transactions with BioXcel LLC (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2017 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Dec. 31, 2024 |
|
| Transactions with BioXcel | ||||||
| Research and development | $ 10,256 | $ 8,032 | $ 14,810 | $ 19,433 | ||
| Selling, general and administrative | 5,609 | 9,450 | 11,308 | 22,715 | ||
| Total operating expenses | 15,972 | 18,400 | 26,239 | 43,145 | ||
| Related Party | ||||||
| Transactions with BioXcel | ||||||
| Other current liabilities | 122 | 122 | $ 107 | |||
| Related Party | BioXcel LLC | ||||||
| Transactions with BioXcel | ||||||
| Monthly agreement option fees | $ 18 | |||||
| Research and development | 115 | 292 | 264 | 478 | ||
| Selling, general and administrative | 17 | 90 | 85 | 138 | ||
| Total operating expenses | 132 | $ 382 | 349 | $ 616 | ||
| Other current liabilities | $ 0 | $ 0 | ||||
| Related Party | BioXcel LLC | Development milestones | ||||||
| Transactions with BioXcel | ||||||
| Potential milestone payments | 10,000 | |||||
| Related Party | BioXcel LLC | Sales milestones | ||||||
| Transactions with BioXcel | ||||||
| Potential milestone payments | $ 30,000 | |||||
| Maximum milestone (as as percent) | 3.00% | |||||
| X | ||||||||||
- Definition Amount of fees per month to be paid to enter into collaborative service agreement option. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of potential maximum payments that could be paid under the collaborative agreement. No definition available.
|
| X | ||||||||||
- Definition Represents the maximum percentage of net sales payable under a collaborative agreement. No definition available.
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|